CARLSBAD, Calif., June 28, 2007 (PRIME NEWSWIRE) -- Alphatec Holdings, Inc. (Nasdaq:ATEC), a leading medical device company focused on the design, development, manufacturing and marketing of products for the surgical treatment of spine disorders, announced today that noted orthopedic surgeon Frank P. Cammisa, Jr., M.D. was appointed to Alphatec's Scientific Advisory Board.
"Dr. Cammisa is one of America's leading spine experts and I am very pleased to have a surgeon of such distinction in the spine industry agree to join our Scientific Advisory Board," said Dirk Kuyper, Alphatec's President and Chief Executive Officer. "Dr. Cammisa's perspective will be instrumental in both the design and marketing of our products. He shares our vision of building Alphatec into the leading medical device company focused on providing innovative solutions targeted at serving the needs of the spinal disorder marketplace."
Frank P. Cammisa, Jr., M.D. is the Chief of the Spine Service at Hospital for Special Surgery located in New York, NY and Associate Professor of Orthopedic Surgery at Weill Medical College of Cornell University located in New York, NY. In addition, Dr. Cammisa is an Associate Scientist -- Research Division at the Hospital for Special Surgery. Dr. Cammisa received his medical degree from College of Physicians and Surgeons at Columbia University and completed his surgical residency at The Presbyterian Hospital and Columbia Presbyterian Medical Center, New York, NY. He completed an orthopedic surgical residency at The Hospital for Special Surgery, New York, NY. Further, Dr. Cammisa completed a fellowship in spine surgery at the University of Miami, Jackson-Memorial Medical Center and The Miami Project to Cure Paralysis in Miami, FL. Dr. Cammisa has earned board certification from the National Board of Medical Examiners, the America Board of Orthopedic Surgery, and the American Board of Orthopedic Surgery. Dr. Cammisa is licensed to practice in California, Connecticut, Washington DC, New Jersey, New York, and Vermont. Dr. Cammisa has affiliations with the American Spine Society, International College of Surgeons, Fellow American College of Surgeons, Cervical Spine Research Society, and International Society for the Study of Lumbar Spine. Dr. Cammisa has won numerous awards including the North American Traveling Fellowship award from American Orthopedic Association, the Spinal Research Award from Eastern Orthopedic Association and the Fellow Scholar Award, Eastern Orthopedic Association.
About Alphatec
Alphatec (Nasdaq:ATEC) designs, develops, in-licenses, manufactures and markets innovative products for the surgical treatment of spine disorders. The company's broad product portfolio and pipeline includes a variety of spinal implant products and systems focused on solutions addressing the cervical, thoracolumbar, intervertebral, minimally invasive, allograft, and motion preservation markets. The company's "surgeons' culture" emphasizes collaboration with spinal surgeons to conceptualize, design and co-develop a broad range of products. State-of-the-art in-house manufacturing capabilities provide a unique competitive advantage, enabling the company to rapidly deliver customized solutions to meet surgeons' and patients' critical needs. Alphatec has 18 issued U.S. patents, one issued foreign patent and 24 pending patent applications, including sixteen pending U.S. applications, four pending international applications and four pending foreign national applications. Alphatec's principal product offerings are primarily focused on the global spine fusion market, which is estimated to approach $5.9 billion in 2007. In addition to its U.S. operations, the company also markets a range of spine and orthopedic products in Japan through its subsidiary, Alphatec Pacific, Inc. For more information, please visit www.alphatecspine.com.
The Alphatec Holdings, Inc. logo is available at http://www.primenewswire.com/newsroom/prs/?pkgid=3520
Forward-Looking Statements
This press release may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainty. Such statements are based on management's current expectations and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These forward-looking statements include, but are not limited to: Alphatec's ability to successfully design, develop, manufacture and market products for the surgical treatment of spine disorders and Alphatec's expectations regarding the continued growth of the U.S. spine market. Alphatec cautions investors that there can be no assurance that actual results or business conditions will not differ materially from those projected or suggested in such forward-looking statements as a result of various factors, including, but not limited to, the following: Alphatec's ability to maintain its level of previously reported sales growth, Alphatec's ability to successfully leverage upon the experience of its Scientific Advisory Board, Alphatec's ability to develop and expand its spine fusion business in the United States and Japan, Alphatec's ability to expand and maintain a successful sales and marketing organization, continuation of favorable third party payor reimbursement for procedures performed using Alphatec's products, unanticipated expenses or liabilities or other adverse events affecting cash flow or Alphatec's ability to achieve profitability, uncertainty of additional funding, uncertainty of success in developing new products or products currently in Alphatec's pipeline, failure to successfully introduce and develop new products, including products related to license agreements, failure to achieve acceptance of Alphatec's products by the surgeon community, failure to obtain FDA clearance or approval for new products, Alphatec's ability to compete with other competing products and with emerging new technologies within and outside of spinal fusion, product liability exposure, patent infringement claims and claims related to Alphatec's intellectual property. Please refer to the risks detailed from time to time in Alphatec's SEC reports, including quarterly reports on Form 10-Q, reports on Form 8-K and annual reports on Form 10-K. Alphatec disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, unless required by law.